Phase II study of XR5000 (DACA), an inhibitor of topoidomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerDITTRICH, Christian; DIERAS, Veronique; KERBRAT, Pierre et al.Investigational new drugs. 2003, Vol 21, Num 3, pp 347-352, issn 0167-6997, 6 p.Article

Recent advances in the treatment of salivary gland cancers : Emphasis on molecular targeted therapyMILANO, Amalia; LONGO, Francesco; BASILE, Maria et al.Oral oncology (1997). 2007, Vol 43, Num 8, pp 729-734, issn 1368-8375, 6 p.Article